VEGF: A Literature Course on What the Published Studies Report

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or any decision involving a drug, biologic or investigational compound. Nothing here is a protocol, a recommendation, or an endorsement. The purpose is to describe what the cited papers actually examined and what their authors reported.

Module 1 — What VEGF is and how it has been studied

VEGF stands for vascular endothelial growth factor. It is not a single molecule but a family of endogenous, secreted signalling glycoproteins produced by many cell types in mammals. The commonly discussed members are VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth factor (PlGF). A 2024 review in Biochimica et Biophysica Acta — Reviews on Cancer summarised VEGF signalling as the central driver of angiogenesis while also describing roles that extend beyond blood-vessel formation, including effects on non-endothelial cell types (PMID 38280470).

Class and origin

In biochemical terms VEGF family members are growth factors — proteins, not short synthetic peptides. That distinction matters when people encounter the phrase "VEGF peptide": VEGF-A in its common secreted isoforms is far larger than the small research peptides usually discussed under that label, and the literature cited here concerns the native protein, its variants and antibodies or traps directed against it. Recombinant VEGF proteins and VEGF-derived fragments are produced for laboratory use; the studies below used them as reagents in cells and animals rather than as therapies given to healthy people.

Forms described in the literature

• VEGF-A — the most studied member; the 2024 review described it as the principal ligand in angiogenic signalling and outlined its receptor interactions (PMID 38280470).
• N-VEGF — a 2022 paper in Cells characterised an N-terminally extended form of VEGF-A, termed N-VEGF, which the authors described as an autoregulatory arm of VEGF-A biology acting inside the cell rather than as a conventional secreted ligand (PMID 35455969).
• VEGF-B — a 2023 paper in Signal Transduction and Targeted Therapy reported that VEGF-B restrained excessive vessel growth by inhibiting the FGF2/FGFR1 pathway, a role distinct from simple pro-angiogenic activity (PMID 37591843). A 2018 PNAS paper reported that VEGF-B behaved as a potent antioxidant in the systems tested (PMID 30249667).
• VEGF-C — measured alongside VEGF-A and VEGF-B in a 2021 histology study of non-hereditary, non-metastatic phaeochromocytoma tissue (PMID 33734425).

How it has been studied

The verified literature on this page falls into four broad designs: narrative and mechanistic reviews (PMID 38280470); cell-culture and molecular experiments, such as the work reporting that VEGF stimulated angiogenesis by promoting mitochondrial function (PMID 29100366); animal and tissue-level physiology, including a 2017 study describing VEGF as a paracrine regulator of conventional outflow facility in the eye (PMID 28358962); and immunohistochemical surveys of human tumour specimens (PMID 34211753).

Limits of the evidence — Module 1

Definitional papers and reviews describe biology, not clinical effect. None of the cited work established that administering a VEGF family protein to a person produces any defined outcome, and the tumour-tissue surveys were observational descriptions of staining patterns rather than interventional studies.

Module 2 — Mechanism as described in the literature

The canonical account, restated in the 2024 review, is that VEGF ligands bind VEGF receptors on endothelial cells and trigger intracellular signalling that promotes endothelial proliferation, migration, survival and permeability, with additional described roles beyond angiogenesis itself (PMID 38280470). Several of the verified papers add layers to that picture.

Metabolic and mitochondrial coupling

A 2017 Oncotarget study reported that VEGF stimulated angiogenesis by promoting mitochondrial functions, linking the growth-factor signal to the energetic state of responding cells rather than to proliferation signalling alone (PMID 29100366). Separately, researchers reported that VEGF-B acted as a potent antioxidant, which situates one family member within redox biology as well as vascular biology (PMID 30249667).

Negative regulation and cross-pathway inhibition

Not all VEGF signalling pushes vessels to grow. The 2023 study reported that VEGF-B prevented excessive angiogenesis by inhibiting the FGF2/FGFR1 pathway, meaning one family member constrained a separate growth-factor axis (PMID 37591843). The 2022 Cells paper described N-VEGF as an autoregulatory element within VEGF-A biology, a feedback arm operating inside the producing cell (PMID 35455969).

Local availability, transport and competition

Where VEGF sits matters as much as how much exists. A 2014 Cell commentary described mechanisms by which one cell population effectively sequesters VEGF from neighbouring cells — captured in its title, "Stealing VEGF from thy neighbor" — framing VEGF availability as a competitive, local resource (PMID 25417099). In neurons, a 2017 study in Frontiers in Molecular Neuroscience reported that VEGF underwent axonal transport dependent on kinesin-1B and microtubule dynamics, describing an intracellular trafficking route for the factor (PMID 29311814). In the anterior eye, researchers reported that VEGF acted as a paracrine regulator of conventional outflow facility, a tissue-level function distinct from new vessel formation (PMID 28358962).

Limits of the evidence — Module 2

Mechanistic findings were generated in defined models — cultured cells, isolated tissues, genetically manipulated animals — and mechanisms demonstrated in one tissue did not automatically transfer to another. The papers described pathways; they did not quantify how those pathways behave in an intact human body, and several proposed mechanisms (mitochondrial coupling, antioxidant activity, autoregulation) have been reported by single research groups rather than replicated across independent laboratories in the set cited here.

Module 3 — Reported outcomes, study by study

The table below summarises what each verified paper examined and what its authors reported. No dose figures are stated because the verified abstracts available for this page did not supply dosing detail that could be reproduced accurately.

Limits of the evidence — Module 3

None of these reports is a controlled clinical trial of VEGF administration in people, and none supports a claim of benefit for any condition. The tumour studies were cross-sectional descriptions of protein staining in tissue; they do not establish cause, direction of effect, or outcome. Several findings came from single reports, and effect sizes, confidence intervals and replication status cannot be summarised from the abstract-level scope of this page.

Module 4 — VEGF Side Effects: What Studies Report

Because VEGF is an endogenous signalling protein, the adverse findings in the literature cluster into two categories: harms attributed to excessive or mislocalised VEGF signalling, and harms or treatment failures observed when VEGF signalling is blocked.

Findings tied to excess or unrestrained signalling

The 2023 study framed excessive angiogenesis as a pathological outcome to be prevented, reporting that VEGF-B limited it by inhibiting the FGF2/FGFR1 pathway — implying that loss of such restraint permits overgrowth of vessels (PMID 37591843). The 2024 review placed VEGF signalling at the centre of pathological angiogenesis in cancer as well as normal vessel development (PMID 38280470). In ocular tissue, researchers reported that VEGF modulated conventional outflow facility, a parameter relevant to intraocular pressure regulation (PMID 28358962).

Findings tied to VEGF blockade or VEGF-mediated damage

A 2024 study in Molecular Therapy — Nucleic Acids reported that the inefficacy of anti-VEGF therapy was reflected in VEGF-mediated photoreceptor degeneration, describing retinal cell loss associated with VEGF signalling in a setting where anti-VEGF treatment did not achieve the intended result (PMID 38689803). The 2014 commentary's account of cells competing for locally available VEGF illustrates why withdrawing or diverting the factor from a tissue can have consequences for the neighbouring cells that depended on it (PMID 25417099).

Association with tumour tissue

Three immunohistochemical studies reported VEGF-family expression in human tumours: phaeochromocytoma specimens expressed VEGF-A, VEGF-B and VEGF-C (PMID 33734425), prostate adenocarcinoma specimens showed VEGF immunoexpression (PMID 34211753), and endometrioid endometrial carcinomas showed VEGF immunoexpression (PMID 36320870). These are observations about tumour biology, not evidence that exogenous VEGF causes tumours.

Limits of the evidence — Module 4

There is no organised human safety dataset for exogenous VEGF administration in the verified literature. The adverse findings above were inferred from disease models, blockade experiments and tissue surveys; none is a tabulated adverse-event profile with frequencies, severity grading or dose-response. Absence of reported harms in these papers is not evidence of safety.

Module 5 — Pharmacokinetics, where data exist

The verified papers on this page did not report human pharmacokinetic parameters — no absorption, plasma half-life, clearance or bioavailability figures are available to summarise, and inventing them would misrepresent the sources. What the literature did describe is disposition at the cellular and tissue level:

• Intracellular retention. Researchers described N-VEGF as an autoregulatory form of VEGF-A operating within the cell rather than acting purely as a secreted ligand (PMID 35455969).
• Directed transport. A 2017 study reported VEGF axonal transport dependent on kinesin-1B and microtubule dynamics, indicating active movement along cytoskeletal tracks in neurons (PMID 29311814).
• Local, paracrine action. VEGF was described as a paracrine regulator of conventional outflow facility, i.e. acting on neighbouring tissue near its site of release (PMID 28358962).
• Competitive local availability. The 2014 commentary described neighbouring cells effectively taking up VEGF at one another's expense, making local concentration a contested variable (PMID 25417099).

Limits of the evidence — Module 5

Tissue-level trafficking is not pharmacokinetics. Without human dosing studies there is no basis for statements about exposure, accumulation or duration of action, and any figure circulating outside the peer-reviewed record cannot be traced to the papers cited here.

Module 6 — Regulatory status, stated factually

Several points can be stated as matters of fact rather than interpretation.

1. VEGF is endogenous. It is a naturally occurring human signalling protein family, described as such throughout the literature (PMID 38280470). Endogenous status confers no regulatory approval on any manufactured product.
2. The approved medicines in this space are anti-VEGF agents, not VEGF itself. Anti-VEGF therapy is an established clinical modality referenced in the retinal literature, where researchers examined cases of therapeutic inefficacy alongside VEGF-mediated photoreceptor degeneration (PMID 38689803). Those agents are prescription biologics used under specialist supervision.
3. Recombinant VEGF proteins are laboratory reagents. They are typically supplied for research use only (RUO). RUO labelling means the material has not been evaluated or authorised for diagnostic or therapeutic use in humans, and it is not a dosage form.
4. Compounding. Pharmacy compounding in the United States operates under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, which require an eligible bulk drug substance and a valid prescription or outsourcing-facility framework. A growth factor supplied as an RUO reagent does not meet those conditions.

This module describes regulatory categories for educational purposes and is not legal advice; regulations differ by country and change over time.

Limits of the evidence — Module 6

Regulatory classification says nothing about biological plausibility, and the scientific papers cited here say nothing about legality. The two questions are answered by different bodies of evidence, and this page does not bridge them.

What the studies did not test

Reading the verified literature closely, the gaps are as instructive as the findings:

• No administration of VEGF to healthy humans. None of the cited papers reported giving a VEGF family protein to healthy volunteers for any purpose, at any dose, by any route.
• No clinical endpoints. The reported endpoints were vessel growth, mitochondrial function, antioxidant activity, transport dynamics, outflow facility, photoreceptor integrity and tissue immunoexpression — not symptoms, function scores, quality of life or survival in treated people.
• No dose-response for exogenous use. Because no human dosing study appears in the verified set, no threshold, ceiling or duration can be described.
• No long-term follow-up. The cell, tissue and model studies did not report extended surveillance for delayed effects.
• No interaction data. Combination with other compounds, drugs or hormones was not evaluated in the cited work.
• No comparison between family members in humans. Although researchers reported that VEGF-B restrained angiogenesis via FGF2/FGFR1 (PMID 37591843) and behaved as an antioxidant (PMID 30249667), those findings came from experimental systems and were not compared head-to-head with VEGF-A in a clinical setting.

The reasonable summary is that VEGF is a well-characterised signalling family with a deep mechanistic literature and, in the papers verified for this page, no human interventional evidence base. Again: this page is for educational purposes only and is not medical advice; consult a licensed physician for any health decision.

References

• VEGF signaling: Role in angiogenesis and beyond (Biochimica et Biophysica Acta — Reviews on Cancer, 2024)
• VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathway (Signal Transduction and Targeted Therapy, 2023)
• VEGF-A/VEGF-B/VEGF-C expressions in non-hereditary, non-metastatic phaeochromocytoma (Histology and Histopathology, 2021)
• N-VEGF, the Autoregulatory Arm of VEGF-A (Cells, 2022)
• Inefficacy of anti-VEGF therapy reflected in VEGF-mediated photoreceptor degeneration (Molecular Therapy — Nucleic Acids, 2024)
• VEGF-B is a potent antioxidant (PNAS, 2018)
• VEGF stimulated the angiogenesis by promoting the mitochondrial functions (Oncotarget, 2017)
• VEGF Immunoexpression in Prostate Adenocarcinoma (Current Health Sciences Journal, 2021)
• Stealing VEGF from thy neighbor (Cell, 2014)
• VEGF Axonal Transport Dependent on Kinesin-1B and Microtubules Dynamics (Frontiers in Molecular Neuroscience, 2017)
• VEGF Immunoexpression in Endometrioid Endometrial Carcinomas (Current Health Sciences Journal, 2022)
• VEGF as a Paracrine Regulator of Conventional Outflow Facility (Investigative Ophthalmology & Visual Science, 2017)